Fosfomycin in chronic urinary infections

Area of Science:

• Urology
• Infectious Diseases
• Pharmacology

Background:

• Serious urinary tract infections (UTIs) often stem from complex etiologies like prostatitis, carcinomas, and lithiasis.
• Recurrent infections pose a significant challenge in managing UTIs.
• Identifying causative pathogens and their antibiotic sensitivities is crucial for effective treatment.

Purpose of the Study:

• To evaluate the efficacy of fosfomycin in treating serious urinary tract infections.
• To assess the microbiological response and clinical outcomes of fosfomycin therapy.
• To determine the effectiveness of fosfomycin against a spectrum of common uropathogens.

Main Methods:

• A study involving 40 patients with serious UTIs of diverse clinical origins.
• Urine cultures were performed to identify bacterial pathogens before treatment.
• Antimicrobial susceptibility testing was conducted to assess pathogen sensitivity to fosfomycin.

Main Results:

• Escherichia coli was the most prevalent pathogen (60%), followed by Klebsiella (15%), P. aeruginosa (15%), and Proteus sp. (15%).
• All isolated pathogens demonstrated pre-treatment sensitivity to fosfomycin.
• Fosfomycin achieved a 71.4% eradication rate of bacteriuria, with 17.2% reinfections and 11.4% treatment failures.

Conclusions:

• Fosfomycin is a highly effective antibiotic for treating serious urinary tract infections, including those with complex underlying conditions.
• The observed high eradication rate and pathogen sensitivity support fosfomycin's utility in managing challenging UTIs.
• The results are considered very satisfactory, highlighting fosfomycin's role in addressing diverse uropathogens in complicated UTI cases.